Pulmonology

 
FDA May End Use of Oral Phenylephrine as Nasal Decongestant Ingredient in OTC Products
November 08, 2024

A decision on ending use of oral phenylephrine as a nasal decongestant in OTC products will be made following public comment on FDA's proposed order.

Social, Racial Disparities in Flu, COVID-19, RSV Vaccine Uptake: Daily Dose
October 31, 2024

Your daily dose of the clinical news you may have missed.

Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose
October 30, 2024

Your daily dose of the clinical news you may have missed.

New Drug Boosts COPD Lung Function, QoL Regardless of Severity: Daily Dose
October 25, 2024

Your daily dose of the clinical news you may have missed.

New Data Highlight Social, Racial Disparities in Flu, COVID-19, RSV Vaccine Uptake
October 17, 2024

IDWeek 2024: Black individuals were less likely to be vaccinated against all 3 respiratory viruses than White individuals, according to new research.

Single vs Multiple Inhaler Triple Therapy for COPD Could Triple Adherence, Persistence: International Data
October 11, 2024

CHEST 2024: Combined data from 4 continents found consistently better adherence/persistence when COPD triple therapy was initiated with a single inhaler.

Early Identification, Treatment of COPD Reduces Exacerbations, Health Care Burden
October 10, 2024

CHEST 2024. Initial treatment for people with COPD should begin early in the disease and leads to significantly reduced risk for exacerbations and inpatient treatment.

Ensifentrine, Novel PDE3, PDE4 Inhibitor, Improves Lung Function, QoL Regardless of COPD Severity
October 09, 2024

The combined bronchodilator/anti-inflammatory agent significantly improved lung function, symptoms and QoL in adults with moderate or severe airflow obstruction.

FDA Approves First-Ever Biologic Medicine for COPD: Daily Dose
October 08, 2024

Your daily dose of the clinical news you may have missed.

Albuterol/Budesonide Reduces Risk of Exacerbation in People with Intermittent, Mild-Persistent Asthma
October 07, 2024

Albuterol/budesonide (Airsupra) has now proven effective as novel combination as-needed rescue medication for adults with asthma regardless of disease severity.